Endo Pharmaceuticals
Endo Pharmaceuticals, merged into Mallinckrodt in July 2025 for $6.7 billion, was reorganized into Keenova Therapeutics (specialty pharma for rare conditions) and Par Health (generics and sterile injectables, spun off November 2025), serving patients and healthcare providers across multiple therapeutic areas.
- Company typePrivate
- Founded1997
- HeadquartersBallsbridge, Ireland
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endo Pharmaceuticals does
Endo Pharmaceuticals is a specialty and generics pharmaceutical company that, following its July 2025 $6.7 billion merger with Mallinckrodt plc, was reorganized into two distinct entities: Keenova Therapeutics (specialty therapeutics) and Par Health (generics and sterile injectables), which was spun off as an independent company in November 2025. Keenova Therapeutics focuses on rare, stigmatized, or unaddressed conditions across immunology, urology, hepatology, ophthalmology, orthopedics, and critical care, with branded products including XIAFLEX (collagenase clostridium histolyticum) for Peyronie's disease and Acthar Gel. Par Health operates as a top 15 U.S. generic manufacturer with approximately 200 products, over 4,000 global employees, and a U.S.-advantaged manufacturing network spanning the U.S. and India for high-quality generics, sterile injectables, and active pharmaceutical ingredients.
The company's core technology centers on complex generics formulation and specialty pharmaceutical development, with regulatory capabilities demonstrated through the first and only FDA-approved generic version of RAVICTI (glycerol phenylbutyrate) oral liquid launched in October 2025 for managing urea cycle disorders. Clinical development includes ongoing Phase 4 studies for XIAFLEX, with updated data presented at major urological conferences (SMSNA, AUA) showing efficacy and tolerability in Peyronie's disease patients. Manufacturing capabilities span sterile injectables and active pharmaceutical ingredients production through U.S.-advantaged facilities.
Endo's business model operates through pharmaceutical supply chains, with revenue generated from one-time sales of branded specialty therapeutics (XIAFLEX, Acthar Gel) and generic pharmaceuticals distributed via wholesalers, hospital systems, and retail pharmacies. The Specialty Generics portfolio generated $896.3 million in fiscal 2024 with 15.4% year-over-year growth, while Acthar Gel generated $485.7 million with 14.2% growth. Post-spin-off, Par Health reported 53.6% total net revenue growth in Q3 2025 compared to the prior year. Go-to-market is executed through enterprise field sales targeting healthcare providers, with marketing channels including medical and scientific conferences and investor relations communications. The combined entity is now positioned as a focused specialty therapeutics company (Keenova) alongside an independent generics and sterile injectables manufacturer (Par Health).
Endo Pharmaceuticals firmographics
Firmographics- Name
- Endo Pharmaceuticals
- Legal name
- Endo, Inc.
- Website
- https://endo.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Short description
- Endo Pharmaceuticals, merged into Mallinckrodt in July 2025 for $6.7 billion, was reorganized into Keenova Therapeutics (specialty pharma for rare conditions) and Par Health (generics and sterile injectables, spun off November 2025), serving patients and healthcare providers across multiple therapeutic areas.
- Ownership category
- akta.pro rank
Endo Pharmaceuticals industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
- akta.pro secondary industries
- Method Development & Validation (ICH/USP) (HLAGADAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Endo Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Ballsbridge
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Endo Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Specialty Pharmaceuticals: Development and commercialization of specialty pharmaceutical products for rare, stigmatized, or unaddressed conditions in immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.
- Generic Pharmaceuticals and Sterile Injectables: Following the merger with Mallinckrodt, Par Health (spun off as independent company) develops and manufactures high-quality generics, sterile injectables, and active pharmaceutical ingredients (APIs) with U.S.-advantaged manufacturing network.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Endo Pharmaceuticals product offering
Product offeringCore offering
No factual content with a resolvable source ID (WX-prefixed) was provided in the input. Therefore, no description of Endo Pharmaceuticals' core offering can be extracted.
Product overview
Endo Pharmaceuticals operates as part of a post-merger structure following the July 2025 $6.7 billion merger with Mallinckrodt plc. After the merger, the combined company spun off its generics and sterile injectables business as Par Health, while the specialty therapeutics operations were rebranded as Keenova Therapeutics in November 2025. Endo's product portfolio includes specialty pharmaceuticals like XIAFLEX® for Peyronie's disease, Acthar Gel, and the recently launched first generic version of RAVICTI® for urea cycle disorders. The Specialty Generics portfolio generated $896.3 million in fiscal 2024 with 15.4% growth. Both entities maintain manufacturing facilities in the U.S. and India with over 4,000 combined employees.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- First and only FDA-approved generic version of RAVICTI (glycerol phenylbutyrate) launched in U.S. market
- +2 more outcomes
Companies that use Endo Pharmaceuticals
Customer profileNamed customers2 records
Segments2 records
Endo Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Endo Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mallinckrodt plccoreMallinckrodt and Endo joined together on July 31, 2025 in a $6.7 billion merger. Following the merger, the combined company spun off its generics and sterile injectables business as Par Health, while rebranding the specialty therapeutics company as Keenova Therapeutics in November 2025.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Endo Pharmaceuticals competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat4 records
Key risks1 record
Customer concentration
Endo Pharmaceuticals social profiles
Digital presenceEndo Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endo Pharmaceuticals leadership team
Management profileNumber of profiles
Endo Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Endo Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endo Pharmaceuticals M&A and investment
M&A and investmentM&A12 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endo Pharmaceuticals
What does Endo Pharmaceuticals do?
No factual content with a resolvable source ID (WX-prefixed) was provided in the input. Therefore, no description of Endo Pharmaceuticals' core offering can be extracted.
Is Endo Pharmaceuticals a public or private company?
Endo Pharmaceuticals is a private company. It is classified as unknown and is currently acquired.
When was Endo Pharmaceuticals founded?
Endo Pharmaceuticals was founded in 1997. It employs 1,001 to 5,000 people.
Where is Endo Pharmaceuticals based?
Endo Pharmaceuticals is headquartered in Ballsbridge, Ireland, in the Europe region.
How does Endo Pharmaceuticals make money?
Two revenue lines are on record. Specialty Pharmaceuticals are the primary driver. The others are generic Pharmaceuticals and Sterile Injectables.
Does Endo Pharmaceuticals have an API?
No public API is recorded for Endo Pharmaceuticals.
What industry is Endo Pharmaceuticals in?
Endo Pharmaceuticals's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGADAB, Method Development & Validation (ICH/USP). Its NAICS code is 3254 and its SIC code is 2834.